Clinical trials: Vinorelbine
Breast Neoplasm, Breast Cancer
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had…
- Conditions
- Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
- Trial name
- NCT05594095
- Testing
- PIK3CA inhibitor, AKT inhibitor, Carrelizumab
- Where
- China
- Volunteers
- 620 people
- Sponsor
- Fudan University
Susceptibility, Genetic, Chemotherapy Effect
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
We plan to carry out a prospective, randomized, open phase III clinical trial which sponsored by the Tianjin Medical University Cancer Hospital and Institute.
- Trial name
- NCT03359694
- Testing
- DT group, ET group, NX group
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HER2-negative Metastatic Breast Cancer
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of post-second-line metastatic breast cancer.
- Trial name
- NCT06533722
- Testing
- Gemcitabine, Vinorelbine, or Eribulin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy
This is a prospective, randomized, open-lable phase III clinical trial evaluating the effectiveness and safety of vinorelbine plus capecitabine as adjuvant treatment for non-pCR Luminal B breast cancer patients after standard…
- Trial name
- NCT04307147
- Testing
- Capecitabine, Vinorelbine
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Fudan University
Breast Cancer
Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)
VENTANA is a "window-of-opportunity" trial that will explore whether, similar to CDK4/6 inhibitors, Oral Metronomic Vinorelbine in combination with Letrozole induces a superior anti-proliferative effect than Letrozole alone.
- Trial name
- NCT02802748
- Testing
- Oral Vinorelbine, Letrozole
- Where
- 10 sites in Spain
- Volunteers
- 60 people
- Sponsor
- SOLTI Breast Cancer Research Group
Cancer
Lapatinib in Combination With Vinorelbine
This is a randomized, parallel-arm, open-label, multi-centre, Phase II study to determine the efficacy and safety of lapatinib in combination with vinorelbine or capecitabine in women with ErbB2 overexpressing metastatic breast…
- Trial name
- VITAL (NCT01013740)
- Testing
- Vinorelbine, Lapatinib, Capecitabine
- Where
- 53 sites in Bulgaria, Chile and 8 more
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054197
- Testing
- gemcitabine hydrochloride, paclitaxel poliglumex, vinorelbine tartrate
- Where
- 10 sites in United States
- Sponsor
- CTI BioPharma
HR+HER2- Breast Cancer
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after…
- Trial name
- NCT06343948
- Testing
- BL-B01D1, Eribulin, Vinorelbine
- Where
- China
- Volunteers
- 383 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
The hypothesize is that tepotinib is more effective than the investigator's choice of treatment in patients with MET-mutated NSCLC who have progressed after at least one first-line treatment.
- Trial name
- COMET (NCT06908993)
- Testing
- Tepotinib, Pemetrexed (Alimta), Vinorelbine
- Where
- 29 sites in France
- Volunteers
- 133 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Metastatic Breast Cancer
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
This is a proof-of-concept study to define efficacy of vinorelbine, cisplatin, disulfiram and copper in CTC_EMT positive refractory metastatic hormone receptor positive, HER2 negative breast cancer.
- Trial name
- NCT04265274
- Testing
- Disulfiram, Vinorelbin, Cisplatin
- Where
- Slovakia
- Sponsor
- National Cancer Institute, Slovakia
Breast Cancer
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Our hypothesis is that this study design, in which bevacizumab is added to one of six single agent chemotherapies with proven activity in metastatic breast cancer, will result in regression or stabilization of this disease in a…
- Trial name
- NCT00476827
- Testing
- Bevacizumab, Docetaxel, CPT-11
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Duke University
Esophageal Squamous Cell Carcinoma, Esophageal Cancer
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
The primary objective is to compare docetaxel plus cisplatin (DP) versus vinorelbine plus cisplatin (NP) in neoadjuvant chemoradiotherapy, in terms of the overall survival and toxicity in patients with Stage IIB or III squamous…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Oesophageal Cancer
- Trial name
- NCT02465736
- Testing
- Docetaxel, Cisplatin, Radiation
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Carcinoma
Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy
The purpose of this study is to determine if radical radiochemotherapy on the mediastinum after lobectomy can be associated with significant long term survival in patients with initially unresectable stage III NSCLC responding to…
- Trial name
- NCT00661011
- Testing
- Lobectomy followed by concomitant mediastinal chemoradiotherapy
- Where
- 12 sites in Belgium, Greece and 1 more
- Volunteers
- 75 people
- Sponsor
- European Lung Cancer Working Party
Ovarian Cancer, Fallopian Tube Cancer
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
This is a phase II study in patients with recurrent platinum resistant or refractory C5 high-grade serous, endometrioid or undifferentiated ovarian, primary peritoneal or fallopian tube cancer.
- Trial name
- NCT03188159
- Testing
- Vinorelbine
- Where
- 2 sites in Australia, Singapore
- Volunteers
- 36 people
- Sponsor
- National University Hospital, Singapore
Non Small Cell Lung Cancer
Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination versus the gemcitabine/docetaxel combination as first line treatment, offers a survival advantage in patients with locally…
- Trial name
- NCT00441740
- Testing
- Vinorelbine, Gemcitabine, Docetaxel
- Where
- 9 sites in Greece
- Volunteers
- 419 people
- Sponsor
- Hellenic Oncology Research Group
Metastatic Breast Cancer
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
The goal of this study is to compare the study drug, sacituzumab govitecan-hziy, versus doctors' treatment of choice in participants with HR+/HER2- metastatic breast cancer (MBC) who have failed at least 2 prior chemotherapy…
- Trial name
- NCT04639986
- Testing
- Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral Product
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 331 people
- Sponsor
- Gilead Sciences
Breast Cancer, Metastatic
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive…
- Trial name
- ASPEN-09-03 (NCT07007559)
- Testing
- Evorpacept (ALX148), Trastuzumab, Paclitaxel
- Where
- 60 sites in United States, Canada and 6 more
- Volunteers
- 120 people
- Sponsor
- ALX Oncology Inc.
Breast Cancer
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations
The purpose of this study is to compare the efficiency and safety between paclitaxel combined with epirubicin and vinorelbine combined with epirubicin when used in neoadjuvant chemotherapy for locally advanced (IIb-IIIc)…
- Trial name
- NCT02628613
- Testing
- Vinorelbine plus Epirubicin, Paclitaxel plus Epirubicin
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Fudan University
Hodgkin Disease Lymphoma
A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
This is an open-label, multicenter, randomized, phase 3 trial to evaluate the efficacy of Penpulimab vs. standard chemotherapy selected by investigator in patients with relapsed or refractory classic Hodgkin's lymphoma.
- Trial name
- NCT05244642
- Testing
- Penpulimab, Investigator's choice of Chemotherapy
- Where
- 6 sites in China
- Volunteers
- 60 people
- Sponsor
- Akeso
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Rationale: Completely resected non-small cell lung cancer (NSCLC) patients with histologically confirmed N2 disease are a heterogeneous population, with 5-year survival rates ranging from 10% to 30%.
- Trial name
- NCT02977169
- Testing
- PORT, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Chest Hospital